<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328548</url>
  </required_header>
  <id_info>
    <org_study_id>09-450</org_study_id>
    <nct_id>NCT01328548</nct_id>
  </id_info>
  <brief_title>Zoster Vaccine Response in the Frail Elderly</brief_title>
  <official_title>Immune and Genetic Correlates of Response to Zoster Vaccine in the Frail Elderly: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the zoster vaccine response in the nursing home elderly
      (80 years or older). As the immune system ages, the response to vaccines is not always as
      strong as in younger people. Previous zoster vaccine studies have excluded nursing home
      residents so the vaccine effect in this population is not known. Furthermore, the immune and
      genetic reasons as to why the vaccine works well in some people but not in others are also
      unknown. The goal of this study is to evaluate why some immune systems respond well to the
      vaccine and why others do not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Deleterious changes in immunity that occur with aging are known as immunosenescence. Such
      changes, particularly in adaptive immunity, may lead to an impaired vaccine response in the
      elderly. Characterizing the immune determinants and the genetic basis for vaccine response in
      the frail elderly is a practical approach to better our understanding of immunosenescence.
      Data on genetic determinants to immunization are sparse, furthermore, to the best of our
      knowledge, none exist in the elderly. In this pilot study, we propose studying the immune
      response to the herpes zoster vaccine and the underlying genetic determinants of the immune
      response in elderly residents of nursing homes.

      The three specific aims of this study are to generate data in order to 1) assess the T-cell
      response to the varicella-zoster virus (VZV) vaccine in the frail elderly; 2) assess whether
      immune (T-cell) phenotypes are associated with a response; 3) test the association between
      immune response genotype sets and T-cell response. We hypothesize that response to the VZV
      vaccine in elderly nonambulatory nursing home residents is a function of characteristic
      T-cell immune phenotypes prior to vaccination and that there are immune genetic polymorphisms
      associated with the response. This study will allow us to generate preliminary data and
      establish feasibility in order to address these questions fully in a larger population in a
      subsequent grant application.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in T-cell Response to the VZV Vaccine in the Frail Elderly</measure>
    <time_frame>6 weeks</time_frame>
    <description>As the primary phenotype, we will compare change in Enzyme-linked immunosorbent spot (ELISPOT) from baseline (i.e., pre and post vaccination). A high baseline T cell response will be defined as ELISPOT = &gt;50 spots and a low baseline response will be ELISPOT = &lt;10 spots.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Immune Parameters Compatible With Inflammaging: CD4+/CD8+ Ratio</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in the nursing home vaccine group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Immune Parameters Compatible With Inflammaging: High T Regulatory Cells</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in the nursing home vaccine group.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Assessment of Immune Parameters Compatible With Inflammaging: TEMRA Cells</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of Tcell populations will be conducted on whole blood using multiparametric flow cytometry prior to immunization to characterize the immunological function of circulating Tcells in each participant.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Immune Parameters Compatible With Inflammaging: High CD8+CD28CD45RA+T Cells</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of Tcell populations will be conducted on whole blood using multiparametric flow cytometry prior to immunization to characterize the immunological function of circulating Tcells in each participant.</description>
  </other_outcome>
  <other_outcome>
    <measure>Testing 150 Candidate Immune Response Genes for SNP Analysis</measure>
    <time_frame>Baseline</time_frame>
    <description>These will include Tolllike receptors, cytokines, chemokines, chemokine receptors, interferons and interferon receptors. Tolllike receptors: TLR1TLR9 Cytokines: ILI1A, ILI1B, IL1RN, IL4, IL5, IL12B, IL13, CSF2 Chemokines: CCL1CCL3, CCL3L1, CCL4CCL8, CCL11, CCL13, CCL15CCL28, CXCL1CXCL14, CXCL16, CX3CL1 Chemokine receptors: CCR1CCR10, CXCR1CXCR6, CX3CR1, XCR1XCR2 Interferons: IFNA1IFNA2, IFNA4IFNA8, IFNA10, IFNA13, IFNA14, IFNA16IFNA17, IFNA21, IFNB1, IFNB3, IFNG, IFNK, IFNW1 Interferon receptors: IFNAR1, IFNAR2, IFNGR1, IFNGR2</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Immune Parameters Compatible With Inflammaging: CD4 Cell Frequency</measure>
    <time_frame>Baseline</time_frame>
    <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in the nursing home vaccine group.</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">241</enrollment>
  <condition>Immune System Diseases</condition>
  <arm_group>
    <arm_group_label>Nursing Home Elderly Cases</arm_group_label>
    <description>Non-ambulatory nursing home residents &gt;= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs (single nucleotide polymorphisms). A case will be considered failure to mount a high response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nursing Home Elderly Controls</arm_group_label>
    <description>Non-ambulatory nursing home residents &gt;= 80 years old will be vaccinated with the zoster vaccine and provide baseline and post-vaccination blood samples. We will assess differences in genotype frequencies between participants with high and low RCF and ELISPOT responses using a candidate gene approach with SNPs. A control will be a participant who mounted an adequate response as defined in primary outcomes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Community dwelling seniors</arm_group_label>
    <description>Community dwelling seniors ages 60-75 will be enrolled as a control group for the laboratory testing. They will be vaccinated and will provide pre- and post-vaccination blood. If nursing home residents do not show a response it is important to know that it is not a failure of the laboratory's measurement of immunogenicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zostavax</intervention_name>
    <arm_group_label>Nursing Home Elderly Cases</arm_group_label>
    <arm_group_label>Nursing Home Elderly Controls</arm_group_label>
    <arm_group_label>Community dwelling seniors</arm_group_label>
    <other_name>Zoster vaccine</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Retained specimens include DNA and blood cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly, non-ambulatory residents of nursing homes.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nursing home resident

          -  greater than or equal to 80 years old

          -  non-ambulatory

        Exclusion Criteria:

          -  less than 80 years old

          -  ambulatory

          -  taking immunosuppressive medication

          -  history of primary or acquired immuno-deficiency states including leukemia, other
             malignant neoplasms affecting the bone marrow or lymphatic system, and AIDS

          -  active untreated tuberculosis

          -  previous receipt of varicella vaccine

          -  residents expected to expire within 30 days, in the opinion of the most responsible
             physician

          -  residents planning to move nursing homes within the year

          -  temporary residents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>80 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark B. Loeb, FRCPC,MD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Macassa Lodge</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <results_first_submitted>March 3, 2016</results_first_submitted>
  <results_first_submitted_qc>March 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2017</results_first_posted>
  <last_update_submitted>March 15, 2018</last_update_submitted>
  <last_update_submitted_qc>March 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>varicella-zoster virus</keyword>
  <keyword>vaccine</keyword>
  <keyword>T-cell</keyword>
  <keyword>genes</keyword>
  <keyword>frail elderly</keyword>
  <keyword>immunosenescence</keyword>
  <keyword>immune and genetic correlates of response to zoster vaccine in the elderly</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nursing Home Vaccine Group</title>
          <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
        </group>
        <group group_id="P2">
          <title>Community Control Vaccine Group</title>
          <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="191"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nursing Home Vaccine Group</title>
          <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
        </group>
        <group group_id="B2">
          <title>Community Control Vaccine Group</title>
          <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="191"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="241"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89.0" spread="4.69"/>
                    <measurement group_id="B2" value="67.3" spread="4.34"/>
                    <measurement group_id="B3" value="84.5" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="241"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in T-cell Response to the VZV Vaccine in the Frail Elderly</title>
        <description>As the primary phenotype, we will compare change in Enzyme-linked immunosorbent spot (ELISPOT) from baseline (i.e., pre and post vaccination). A high baseline T cell response will be defined as ELISPOT = &gt;50 spots and a low baseline response will be ELISPOT = &lt;10 spots.</description>
        <time_frame>6 weeks</time_frame>
        <population>IFN-gamma T cell ELISpot assay (sfu) against VZV taken prior to vaccination and 6 weeks post vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Nursing Home Vaccine Group</title>
            <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
          </group>
          <group group_id="O2">
            <title>Community Control Vaccine Group</title>
            <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in T-cell Response to the VZV Vaccine in the Frail Elderly</title>
          <description>As the primary phenotype, we will compare change in Enzyme-linked immunosorbent spot (ELISPOT) from baseline (i.e., pre and post vaccination). A high baseline T cell response will be defined as ELISPOT = &gt;50 spots and a low baseline response will be ELISPOT = &lt;10 spots.</description>
          <population>IFN-gamma T cell ELISpot assay (sfu) against VZV taken prior to vaccination and 6 weeks post vaccination</population>
          <units>Spot Forming Units per 10^6 PBMC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-vaccine IFN-gamma T cell ELISpot assay count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.17" spread="54.84"/>
                    <measurement group_id="O2" value="78.17" spread="65.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post- vaccine IFN-gamma T cell ELISpot assay count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.22" spread="72.56"/>
                    <measurement group_id="O2" value="120.56" spread="76.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Immune Parameters Compatible With Inflammaging: CD4+/CD8+ Ratio</title>
        <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in the nursing home vaccine group.</description>
        <time_frame>Baseline</time_frame>
        <population>Predictor variables were assessed only among the frail elderly, the community control group served as a control for immunogenicity only.</population>
        <group_list>
          <group group_id="O1">
            <title>Nursing Home Vaccine Group</title>
            <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
          </group>
          <group group_id="O2">
            <title>Community Control Vaccine Group</title>
            <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Immune Parameters Compatible With Inflammaging: CD4+/CD8+ Ratio</title>
          <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in the nursing home vaccine group.</description>
          <population>Predictor variables were assessed only among the frail elderly, the community control group served as a control for immunogenicity only.</population>
          <units>T-cell ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="2.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Immune Parameters Compatible With Inflammaging: High T Regulatory Cells</title>
        <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in the nursing home vaccine group.</description>
        <time_frame>Baseline</time_frame>
        <population>Predictor variables were assessed only among the frail elderly, the community control group served as a control for immunogenicity only.</population>
        <group_list>
          <group group_id="O1">
            <title>Nursing Home Vaccine Group</title>
            <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
          </group>
          <group group_id="O2">
            <title>Community Control Vaccine Group</title>
            <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Immune Parameters Compatible With Inflammaging: High T Regulatory Cells</title>
          <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in the nursing home vaccine group.</description>
          <population>Predictor variables were assessed only among the frail elderly, the community control group served as a control for immunogenicity only.</population>
          <units>% of peripheral blood mononuclear cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Assessment of Immune Parameters Compatible With Inflammaging: TEMRA Cells</title>
        <description>Characterization of Tcell populations will be conducted on whole blood using multiparametric flow cytometry prior to immunization to characterize the immunological function of circulating Tcells in each participant.</description>
        <time_frame>Baseline</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Nursing Home Vaccine Group</title>
            <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
          </group>
          <group group_id="O2">
            <title>Community Control Vaccine Group</title>
            <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Immune Parameters Compatible With Inflammaging: TEMRA Cells</title>
          <description>Characterization of Tcell populations will be conducted on whole blood using multiparametric flow cytometry prior to immunization to characterize the immunological function of circulating Tcells in each participant.</description>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Assessment of Immune Parameters Compatible With Inflammaging: High CD8+CD28CD45RA+T Cells</title>
        <description>Characterization of Tcell populations will be conducted on whole blood using multiparametric flow cytometry prior to immunization to characterize the immunological function of circulating Tcells in each participant.</description>
        <time_frame>Baseline</time_frame>
        <population>Data not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Nursing Home Vaccine Group</title>
            <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
          </group>
          <group group_id="O2">
            <title>Community Control Vaccine Group</title>
            <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Immune Parameters Compatible With Inflammaging: High CD8+CD28CD45RA+T Cells</title>
          <description>Characterization of Tcell populations will be conducted on whole blood using multiparametric flow cytometry prior to immunization to characterize the immunological function of circulating Tcells in each participant.</description>
          <population>Data not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Testing 150 Candidate Immune Response Genes for SNP Analysis</title>
        <description>These will include Tolllike receptors, cytokines, chemokines, chemokine receptors, interferons and interferon receptors. Tolllike receptors: TLR1TLR9 Cytokines: ILI1A, ILI1B, IL1RN, IL4, IL5, IL12B, IL13, CSF2 Chemokines: CCL1CCL3, CCL3L1, CCL4CCL8, CCL11, CCL13, CCL15CCL28, CXCL1CXCL14, CXCL16, CX3CL1 Chemokine receptors: CCR1CCR10, CXCR1CXCR6, CX3CR1, XCR1XCR2 Interferons: IFNA1IFNA2, IFNA4IFNA8, IFNA10, IFNA13, IFNA14, IFNA16IFNA17, IFNA21, IFNB1, IFNB3, IFNG, IFNK, IFNW1 Interferon receptors: IFNAR1, IFNAR2, IFNGR1, IFNGR2</description>
        <time_frame>Baseline</time_frame>
        <population>Genotyping was not conducted because of insufficient resources.</population>
        <group_list>
          <group group_id="O1">
            <title>Nursing Home Vaccine Group</title>
            <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
          </group>
          <group group_id="O2">
            <title>Community Control Vaccine Group</title>
            <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Testing 150 Candidate Immune Response Genes for SNP Analysis</title>
          <description>These will include Tolllike receptors, cytokines, chemokines, chemokine receptors, interferons and interferon receptors. Tolllike receptors: TLR1TLR9 Cytokines: ILI1A, ILI1B, IL1RN, IL4, IL5, IL12B, IL13, CSF2 Chemokines: CCL1CCL3, CCL3L1, CCL4CCL8, CCL11, CCL13, CCL15CCL28, CXCL1CXCL14, CXCL16, CX3CL1 Chemokine receptors: CCR1CCR10, CXCR1CXCR6, CX3CR1, XCR1XCR2 Interferons: IFNA1IFNA2, IFNA4IFNA8, IFNA10, IFNA13, IFNA14, IFNA16IFNA17, IFNA21, IFNB1, IFNB3, IFNG, IFNK, IFNW1 Interferon receptors: IFNAR1, IFNAR2, IFNGR1, IFNGR2</description>
          <population>Genotyping was not conducted because of insufficient resources.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Assessment of Immune Parameters Compatible With Inflammaging: CD4 Cell Frequency</title>
        <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in the nursing home vaccine group.</description>
        <time_frame>Baseline</time_frame>
        <population>Predictor variables were assessed only among the frail elderly, the community control group served as a control for immunogenicity only.</population>
        <group_list>
          <group group_id="O1">
            <title>Nursing Home Vaccine Group</title>
            <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
          </group>
          <group group_id="O2">
            <title>Community Control Vaccine Group</title>
            <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Immune Parameters Compatible With Inflammaging: CD4 Cell Frequency</title>
          <description>Characterization of T-cell populations will be conducted on whole blood using multi-parametric flow cytometry prior to immunization to characterize the immunological function of circulating T-cells in the nursing home vaccine group.</description>
          <population>Predictor variables were assessed only among the frail elderly, the community control group served as a control for immunogenicity only.</population>
          <units>% of peripheral blood mononuclear cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="186"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.24" spread="15.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nursing Home Vaccine Group</title>
          <description>Nursing home residents &gt;= 80 years vaccinated with the ZOSTAVAX zoster vaccine</description>
        </group>
        <group group_id="E2">
          <title>Community Control Vaccine Group</title>
          <description>Community dwelling seniors ages 60-75 years vaccinated with the Zostavax zoster vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pre-existing fragile health and advanced age</sub_title>
                <description>Non-vaccine related death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Advanced age and medical issues (Parkinson's disease)</sub_title>
                <description>Non-vaccine related death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Progressive renal failure</sub_title>
                <description>Non-vaccine related death</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="191"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Emesis/Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="191"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain/Soreness in arm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="191"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Redness/Swelling in arm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="191"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="191"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mark Loeb</name_or_title>
      <organization>McMaster University</organization>
      <phone>905 515 9140 ext 26679</phone>
      <email>loebm@mcmaster.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

